Oral care program for patients with head and neck cancer
Official title: Evaluation of an Oral Care Programme for Patients Undergoing Treatment for Head and Neck Cancer Regarding Mucositis, Oral Health, Epigenetic Modifications, Patient-related Factors, Quality of Life and Health Economy
Run by Göteborg University · NCT03481647 · Data updated 2026-11-12
This study tests if a special oral care program can help people with head and neck cancer have less mouth soreness during their treatment compared to standard care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Göteborg University Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (Gothenburg and 1 other locations) |
| Status | Recruiting |
| Started | January 8, 2018 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | April 20, 2025 |
| Trial ID | NCT03481647 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients scheduled to receive full-dose curative radiation therapy that includes major salivary glands in the radiation field.
✕Probably not a fit
Patients with recurrent cancer or severe cognitive impairment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the impact of an intensified oral care program on the prevalence, severity, and duration of mucositis in patients undergoing treatment for head and neck cancer. Participants will receive professional oral care and will be instructed to perform daily rinses with a saline/bicarbonate solution. The program includes weekly professional care and the use of an oral care diary to track hygiene practices. A control group will receive standard oral care once a week for comparison.
Why it matters
Potential benefit: If successful, this program could significantly reduce the incidence and severity of mucositis, improving the quality of life for head and neck cancer patients during treatment.
How similar studies have gone: Other studies have shown that improved oral care can positively impact mucositis in cancer patients, suggesting this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients scheduled to receive full dose of curative RT including major salivary glands in the radiation field Exclusion Criteria: * Patients with recurrent cancer * Patients with severe cognitive impairment.
Where it's running
-
Länssjukhuset Ryhov
Jönköping, Sweden Recruiting -
Institute of odontology
Gothenburg, Sweden Active not recruiting
Study contacts
- Principal investigator: Annica Almståhl, Assoc.prof — Göteborg University
- Study coordinator: Annica Almståhl, Assoc.prof
- Email: annica.almstahl@odontologi.gu.se
- Phone: +46317863208
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Phenotype-based Pain Guidance for Head and Neck Cancer-Related Pain (pilot)
This pilot test sees if tailoring pain treatment to a patient’s pain type can reduce head and neck cancer pain in adults who haven’t started cancer treatment yet.
-
Airway ultrasound in head and neck cancer patients
This observational study tests whether neck ultrasound measurements of the airway match CT measurements in adults with maxillofacial cancer undergoing surgery with anesthesia.
-
Safe use of metformin and naproxen to help prevent cancer in people with Fanconi anemia
This study tests whether metformin and naproxen can lower the chance of cancer developing in adults with Fanconi anemia.
-
Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer
In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.
-
SumMET: Targeted radioligand therapy for c-MET–positive solid tumors
This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.
-
Using Silverlon for head and neck patients with tracheostomies
This early-phase study tests whether Silverlon dressings can prevent severe skin reactions under tracheostomy collars in adults with head and neck cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.